KSQ 427
Alternative Names: KSQ-427Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator KSQ Therapeutics
- Class Antineoplastics; Purines; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Ubiquitin-specific protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Cancer in USA
- 01 Sep 2020 Preclinical trials in Cancer in USA before September 2020
- 19 Dec 2019 KSQ Therapeutics has patents pending for the methods and use of ubiquitin-specific-processing protease 1 inhibitors in World